TheraCell and AlloSource Announce Second Patent for Bone Fiber Technology
Northridge, Calif. and Centennial, Colo. — Mar. 9, 2017 — TheraCell, a regenerative medicine company, today announced it was awarded a second patent for its demineralized bone fiber (DBF™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,572,912, titled Demineralized bone fibers having controlled geometry and shapes and methods thereof, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry.
TheraCell’s DBF™ technology is incorporated into two innovative demineralized cortical fiber allografts, AlloFuse® Cortical Fibers and AlloFuse® Fiber Boat, commercialized by AlloSource, one of the nation’s largest providers of cartilage, cellular, bone, skin and softQtissue allografts for use in surgical procedures to advance patient healing.
The TheraCell demineralized bone fiber is an exciting new biomaterial that appears to perform very well in the pre clinical studies that I have done. The fibers have a nano topography that is cell friendly, based on in vitro and in vivo experiments that coupled with the fiber geometry and lack of excipients makes an easily handled high performance bone graft material”, said Professor Bill Walsh, UNSW Australia.
AlloSource’s AlloFuse Cortical Fibers and AlloFuse Fiber Boat may be appropriate to fill bone voids or cages in spinal and orthopedic procedures. Both AlloFuse Fiber products contain demineralized cortical bone and are designed for fluid absorbency. “This second patent shows TheraCell’s dedication to advancing the science behind demineralized bone fiber allografts,” said Kerr Holbrook, AlloSource Chief Commercial Officer. “Including this patented technology in AlloSource’s product portfolio is important to providing our surgeon customers solutions to help patients in need, while continuing to fully honor our tissue donors.”
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and softQtissue allografts to advance patient healing. For more than 20 years, AlloSource’s products have bridged the proven science of allografts with the advanced technology of cells, offering lifeQsaving and lifeQenhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world’s largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country's most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.
About TheraCell, Inc.
TheraCell, Inc. is a regenerative medicine company developing the next generation of advanced technologies for tissue repair for both the human and veterinary markets. TheraCell has three synergistic technology platforms. The first of these is a proprietary process for making demineralized bone fibers (DBF™). The second platform is an oxygenation technology. Oxygenation leads to improved tissue regeneration. The third technology platform is a point of care stem cell isolation and purification system. Founded in 2008, the firm is headquartered in Los Angeles and maintains offices, laboratories and production facilities in Littleton, MA. www.theracellinc.com. DBF™ is a trademark of TheraCell, Inc.